Boston Scientific Corporation BSX NYSE

Boston Scientific Corporation (BSX) has shown strong revenue growth over the past 3 years, expanding from $12.7B to $20.1B (average +16.6%/yr). Net income reached $2.9B, reflecting exceptional earnings expansion at +66.8%/yr on average. The net profit margin is 14.4%, which is moderate. The company has maintained profitability in all 4 of the past 4 years, demonstrating a consistent earnings track record. The gross margin is 69% (high), with a +0.6pp trend over the period. With a $95B market cap and MOAT composite score of 80/100, the company has a strong competitive position.

Criteria proven by this page:

• GROWTH (90/100, Pass) — proving strong growth momentum
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 35-year history, the company was profitable in 24 of 35 years — a mixed long-term record
• INCOME (55/100, Partial) — the company is profitable but margin is below 15%
• MOAT (80/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 80/100 with 5/7 criteria passed.